What is the 13F Pro Quality Score for CMPS?

13F Pro ranks COMPASS Pathways plc (CMPS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CMPS's current score at https://13fpro.ai/research/CMPS (free sign-up required for the full ranking).

Which hedge funds own the most CMPS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CMPS include Deep Track Capital,, RTW INVESTMENTS,, MARSHALL WACE, LLP. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CMPS as soon as new 13F filings post.

Where does 13F Pro source CMPS data?

All COMPASS Pathways plc fundamentals and ownership data come directly from SEC EDGAR. COMPASS Pathways plc files with the SEC under CIK 1816590. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CMPS in?

COMPASS Pathways plc (CMPS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CMPS research updated on 13F Pro?

CMPS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

COMPASS Pathways plc(CMPS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1816590 CMPS stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CMPS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for COMPASS Pathways plc (CMPS), a Healthcare sector company. CMPS is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), COMPASS Pathways plc reports net income of $91.2M, free cash flow of $-47.9M. Top institutional holders of CMPS by reported 13-F value include Deep Track Capital,, RTW INVESTMENTS,, MARSHALL WACE, LLP, based on the most recent SEC filings. CMPS trades on the Nasdaq exchange and files with the SEC under CIK 1816590. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CMPS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for COMPASS Pathways plc directly from SEC EDGAR.

Net Income

Q1 2026

$91.2M

Free Cash Flow

Q1 2026

$-47.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-73.9% YoY

$-269.8MFY 2025

FY22 $-91.5MFY23 $-118.5MFY24 $-155.1MFY25 $-269.8M

Operating Income

-0.5% YoY

$-179.0MFY 2025

FY22 $-110.4MFY23 $-136.9MFY24 $-178.2MFY25 $-179.0M

EPS (Diluted)

-33.9% YoY

$-3.08FY 2025

FY22 $-2.16FY23 $-2.32FY24 $-2.30FY25 $-3.08

Total Assets

-1.6% YoY

$210.3MFY 2025

FY22 $197.3MFY23 $276.0MFY24 $213.7MFY25 $210.3M

Total Debt

+61.9% YoY

$66.7MFY 2025

FY22 $0.00FY23 $28.8MFY24 $41.2MFY25 $66.7M

Op. Cash Flow

-31.9% YoY

$-157.2MFY 2025

FY22 $-105.5MFY23 $-97.4MFY24 $-119.2MFY25 $-157.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Net Income	$-269.8M -73.9%	$-155.1M -30.9%	$-118.5M -29.5%	$-91.5M -27.5%	$-71.7M -265.8%	$-19.6M
Operating Income	$-179.0M -0.5%	$-178.2M -30.2%	$-136.9M -24.0%	$-110.4M -32.7%	$-83.2M -292.9%	$-21.2M
EPS (Diluted)	$-3.08 -33.9%	$-2.30 +0.9%	$-2.32 -7.4%	$-2.16 -20.7%	$-1.79 -501.5%	$-0.30
Total Assets	$210.3M -1.6%	$213.7M -22.6%	$276.0M +39.9%	$197.3M -34.4%	$300.9M +829.0%	$32.4M
Total Debt	$66.7M +61.9%	$41.2M +43.2%	$28.8M	$0.00	—	—
Operating Cash Flow	$-157.2M -31.9%	$-119.2M -22.4%	$-97.4M +7.7%	$-105.5M -55.7%	$-67.7M -280.3%	$-17.8M

AI Insight: CMPS Financial Trends

COMPASS swung to $91M net income in Q1 2026 after massive Q3–Q4 2025 losses, but operating losses persist and equity volatility signals financial distress.

• Net income recovered to $91M in Q1 2026 from $-138M in Q3 2025, a $229M swing in two quarters.

• Operating cash outflow narrowed to $-48M in Q1 2026 from $-42M in Q4 2025, but remains persistently negative.

• Total debt rose to $67M by Q1 2026 from $29M in Q2 2024, while equity crashed to $-53M in Q4 2025 before rebounding to $327M.

⚠ Operating income remains deeply negative ($-43M in Q1 2026) despite net income recovery—suggests non-operating gains masking core business deterioration.

⚠ Equity swung from $-53M (negative) in Q4 2025 to $327M in Q1 2026—extreme volatility raises questions about accounting adjustments or major financing event.

AI Insight: CMPS Ratio Trends

CMPS swung to profitability in Q1 2026 with ROE of 111.7%, but negative ROIC signals value destruction despite earnings recovery.

• ROE and ROA pivoted sharply positive in Q1 2026 (111.7% and 68.6%) from deeply negative prior quarters, indicating return to profitability.

• Leverage normalized to 0.15 D/E in Q1 2026 from 1.51 in Q3 2025, suggesting material balance sheet deleveraging or capital restructuring.

• ROIC remained sharply negative at -45.5% in Q1 2026 despite earnings recovery, indicating capital is still not generating returns.

⚠ Q3 2025 and Q4 2025 data gaps and D/E spike to 1.51 in Q3 2025 merit clarification on financing events or accounting changes.

⚠ Profitability in Q1 2026 could be one-time; prior 9 quarters showed consistent losses. Sustainability of earnings recovery unproven.

Get alerted when CMPS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for COMPASS Pathways plc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CMPS

Deep Track Capital, LP
$67.3M12,161,496 sh
RTW INVESTMENTS, LP
$58.8M10,632,390 sh
MARSHALL WACE, LLP
$22.3M4,038,335 sh
TANG CAPITAL MANAGEMENT LLC
$22.1M4,002,200 sh
BIT Capital GmbH
$19.3M3,491,234 sh
ARK Investment Management LLC
$18.3M3,301,050 sh
MILLENNIUM MANAGEMENT LLC
$17.4M3,138,522 sh
GMT CAPITAL CORP
$17.0M3,078,536 sh
TWO SIGMA INVESTMENTS, LP
$14.3M2,583,499 sh
DAFNA Capital Management LLC
$13.4M2,418,882 sh

Fund	Value	Shares
Deep Track Capital, LP	$67.3M	12,161,496
RTW INVESTMENTS, LP	$58.8M	10,632,390
MARSHALL WACE, LLP	$22.3M	4,038,335
TANG CAPITAL MANAGEMENT LLC	$22.1M	4,002,200
BIT Capital GmbH	$19.3M	3,491,234
ARK Investment Management LLC	$18.3M	3,301,050
MILLENNIUM MANAGEMENT LLC	$17.4M	3,138,522
GMT CAPITAL CORP	$17.0M	3,078,536
TWO SIGMA INVESTMENTS, LP	$14.3M	2,583,499
DAFNA Capital Management LLC	$13.4M	2,418,882

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CMPS on your watchlist

Track score changes the day COMPASS Pathways plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CMPS a good stock to buy?

13F Pro's AI-powered analysis of COMPASS Pathways plc (CMPS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CMPS are available on the CMPS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CMPS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CMPS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of COMPASS Pathways plc's investment landscape.